All AbMole products are for research use only, cannot be used for human consumption.
Salidroside suppressed OGD/re-oxygenation-induced reactive oxygen species (ROS) production, p53 mitochondrial translocation and cyclophilin D (Cyp-D) association as well as mitochondrial membrane potential (MMP) decrease in H9c2 cells. Salidroside activated Akt and promoted transcription of NF-E2-related factor 2 (Nrf2)-regulated genes (heme oxygenase-1 (HO-1) and quinone oxidoreductase 1 (NQO-1)). Salidroside alleviated the pulmonary symptoms of PQ-induced ALI, at least partially, by repressing inflammatory cell infiltration and the expression of TGF-β1 resulting in delayed lung fibrosis. Salidroside exerts a protective effect in CLP-induced sepsis by attenuating the proinflammatory responses, enhancing bacterial clearance, and preserving adaptive immunity. Salidroside may be a promising therapeutic strategy for the treatment of sepsis. Salidroside decreased the ST elevation induced by ISO, decreased serum levels of CK-MB, LDH, TNF-α, IL-6, SOD, and MDA. In addition, Salidroside increased SOD activity and decreased MDA content in myocardial tissue.Salidroside also decreased Nox2 and 4, NF-κBP65, P-NF-κBP65, and AP1 protein levels in the heart.
| Cell Experiment | |
|---|---|
| Cell lines | MDA-MB-231 cells |
| Preparation method | MDA-MB-231 cells were treated with 10-μM salidroside for 24 h, and MCF-7 cells were treated with 20-μM salidroside for 24 h. |
| Concentrations | 10 μM |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | ICR mice that were 8 weeks of age (18–22 g) |
| Formulation | Not mentioned |
| Dosages | 12 and 24 mg/kg |
| Administration | i.g. |
| Molecular Weight | 300.3 |
| Formula | C14H20O7 |
| CAS Number | 10338-51-9 |
| Form | Solid |
| Solubility (25°C) | DMSO 60mg/mL Water 60mg/mL Ethanol 4mg/mL |
| Storage | 2-8°C, protect from light |
| Related mTOR Products |
|---|
| AZD8055
AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase (both complexes mTORC1 and mTORC2) with an IC50 of 0.8 nM. |
| Deforolimus
Deforolimus (also known as AP23573 and MK-8669) is an investigational targeted and small-molecule mTOR inhibitor. *The compound is unstable in solutions, freshly prepared is recommended |
| Everolimus
Everolimus (RAD001) also known as SDZ-RAD and Certican is an mTOR inhibitor with IC50 of 0.63 nM. |
| KU-0063794
KU-0063794 is a potent and selective mTOR inhibitor with IC50 values of approximately 10 nM for mTORC1 and mTORC2. |
| WYE-354
WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
